ADARx Pharmaceuticals Inc. (Ticker: ADRX US) is a U.S. late-stage biotechnology company developing RNA-targeted therapeutics across complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic diseases, including obesity. The company has developed technologies designed to selectively control the expression of disease-related targets and is advancing a pipeline of RNA therapeutic candidates. ADARx also has a collaboration and license option agreement with AbbVie covering siRNA therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

ADARx plans to list on Nasdaq on September 25, 2026, following expected pricing on September 24. The company is offering 21.875 million shares at $15-$17 per share, representing an IPO size of approximately $350 million at the midpoint. The offering consists entirely of primary shares, with proceeds therefore going to the company before fees and expenses. J.P. Morgan, Morgan Stanley, TD Cowen and UBS are acting as bookrunners.